Loading patent…
AssigneeMarine Polymer Technologies, Inc.
InventorsJohn N. Vournakis, Sergio Finkielsztein, Ernest R. Pariser, Mike Helton
Estimating the term…
The present invention relates to a purified, easily produced poly-β-1→4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a β-1→4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.
A biocompatible and immunoneutral poly-β-1→4-N-acetylglucosamine comprising about 4,000 to about 150,000 N-acetylglucosamine monosaccharides covalently attached in a β-1→4 conformation and having a molecular weight of about 800,000 daltons to about 30 million daltons.
A biocompatible and immunoneutral poly-β-1→4-N-acetylglucosamine comprising about 4,000 to about 150,000 N-acetylglucosamine monosaccharides covalently attached in a β-1→4 conformation and having a molecular weight of about 800,000 daltons to about 30 million daltons in which at least one N-acetylglucosamine monosaccharide has been deacetylated.
A biocompatible and immunoneutral poly-β-1→4-glucosamine comprising about 4,000 to about 150,000 glucosamne monosaccharides covalently attached in a β-1→4 conformation, and having a molecular weight of about 640,000 daltons to about 24 million daltons.
A biocompatible and immunoneutral poly-β-1→4-glucosamine comprising about 4,000 to about 150,000 glucosamine monosaccharides covalently attached in a β-1→4 conformation, wherein at least one glucosamine monosaccharide has been acetylated.
A biocompatible poly-β-1→4-N-acetylglucosamine comprising about 4,000 to about 150,000 N-acetylglucosaniine monosaccharides covalently attached in a β-1→4 conformation and having a molecular weight of about 800,000 daltons to about 30 million daltons.
A biocompatible poly-β-1→4-N-acetylglucosamine comprising about 4,000 to about 150,000 N-acetylglucosarnine monosaccharides covalently attached in a β-1→4 conformation and having a molecular weight of about 800,000 daltons to about 30 million daltons in which at least one N-acetylglucosamine monosaccharide has been deacetylated.
The biocompatible poly-β-1→4-N-acetylglucosamine of any one of claims which has an elution test score of 0.
The biocompatible poly-β-1→4-N-acetylglucosamine of any one of claims which has an elution test score of 2.
A biocompatible poly-β-1→4-glucosamine comprising about 4,000 to about 150,000 glucosamine monosaccharides covalently attached in a β-1→4 conformation, and having a molecular weight of about 640,000 daltons to about 24 million daltons.
A biocompatible poly-β-1→4-glucosamine comprising about 4,000 to about 150,000 glucosamine monosaccharides covalently attached in a β-1→4 conformation, wherein at least one glucosamine monosaccharide has been acetylated.
Dependencies are inferred from the claim text.